This record is currently in review state, the data hasn’t been validated yet.
A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies
De Luca, Roberto
Manz, Markus G
- Journal Article
A novel dual-cytokine–antibody fusion protein, consisting of an antibody directed against CD38 [a tumor-associated antigen mainly expressed on the surface of multiple myeloma (MM) cells], simultaneously fused to both tumor necrosis factor ligand superfamily member 10 (TRAIL) and interleukin-2 (IL2), was designed, expressed and purified to homogeneity. The novel fusion protein, termed IL2-αCD38-αCD38-scTRAIL, was able to selectively recognize its cognate antigen expressed on the surface of MM and lymphoma cell lines, as evidenced by flow cytometry analysis. Moreover, the targeted version of TRAIL was able to induce cancer cell death in vitro, both with MM cell lines and with fresh isolates from the bone marrow of MM patients. The experiments provide a rationale for possible future applications of IL2-αCD38-αCD38-scTRAIL for the treatment of patients with MM or other CD38-positive malignancies Show more
Journal / seriesProtein Engineering, Design and Selection
Pages / Article No.
PublisherOxford University Press (OUP)
Organisational unit03463 - Neri, Dario / Neri, Dario
670603 - Fulfilling Paul Ehrlich’s Dream: therapeutics with activation on demand (EC)
163479 - Understanding and Exploiting the Molecular Targeting of Tumor Neo-vasculature (SNF)
MoreShow all metadata